Company / Operating Cash Flow
VYNE Therapeutics Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$34.0M
FY2025
5-year range
-$137.1M / -$25.3M
FY2021-FY2025
Trend
-34.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$29M to -$34M over the past 2 years.
Based on SEC 10-K filings.
-$34M in FY2025.
Declined from -$29M to -$34M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 34.1% year-over-year.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$34.0M | -34.1% |
| FY2024 | -$25.3M | +13.2% |
| FY2023 | -$29.2M | +48.2% |
| FY2022 | -$56.4M | +58.9% |
| FY2021 | -$137.1M | -99.6% |
| FY2020 | -$68.7M | -143.3% |
| FY2019 | -$28.2M | -1146.0% |
| FY2018 | -$2.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026